Enliven Therapeutics (ELVN) Depreciation & Amortization (CF) (2019 - 2026)

Enliven Therapeutics has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $14000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 81.08% year-over-year to $14000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $240000.0 (down 18.92% YoY) and the FY2025 annual result came in at $300000.0, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) eased to $14000.0 in Q1 2026 per ELVN's latest filing, from $83000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $39.0 million in Q1 2022 and troughed at $14000.0 in Q1 2026.
• A 5-year average of $2.4 million and a median of $74000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) surged 155900.0% in 2022, then slumped 99.83% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $49000.0 in 2022, then surged by 63.27% to $80000.0 in 2023, then decreased by 21.25% to $63000.0 in 2024, then surged by 31.75% to $83000.0 in 2025, then slumped by 83.13% to $14000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $14000.0, $83000.0, and $62000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.